Trial Profile
Use of Rituximab in the treatment of extensive chronic graft versus host disease after allogenic stem cells transplantation.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jul 2011
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 29 Jul 2011 New trial record